RxDoctor Payments DataLook up a doctor →

Ronald Liskanich, DO

Procedural Dermatology · Upland, CANPI 1245391820

Payments from drug & device makers

$23,777in general payments, 2019–2025

Across 625 payments — averaging $38.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$2K
  • LEO Pharma Inc.$2K
  • Galderma Laboratories, L.p.$2K
  • Sanofi$1K
  • Amgen$1K
  • plus $13K from 38 others

What the payments were for

  • Speaking & faculty fees$4672%
  • Food & beverage$22,92096%
  • Education$3902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,777 in reported general payments places this provider in the 80th percentile of 108 procedural dermatology providers in California.

See all procedural dermatology providers in California

Medicare billing

Part B allowed, 2024
$249,193
Medicare patients
646
Services billed
3,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$68,339
Clobetasol Propionate38$3,782
Ketoconazole143$3,227
Pimecrolimus12$2,619
Tacrolimus22$2,417
Fluorouracil30$2,313
Clindamycin Phosphate56$2,212
Alclometasone Dipropionate38$1,501
Triamcinolone Acetonide125$1,423
Desonide27$1,279
Metronidazole29$1,169
Doxycycline Hyclate44$1,104
Betamethasone Dipropionate26$1,051
Mupirocin156$998
ValacyclovirValacyclovir Hcl16$755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,275$68,33914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 108 procedural dermatology providers in California.

Other procedural dermatology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →